Encephalitis Caused by Jamestown Canyon Virus in a Liver Transplant Patient, North Carolina, USA, 2017

Emily J. Ciccone,1,3 Alena J. Markmann,1 Megan L. Srinivas,3,5 Kara J. Levinson,4 Melissa B. Miller,6 David van Duin,7,8 and Cynthia L. Gay1

1Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA, 2Broadlawns Medical Center, Des Moines, Iowa, USA, 3Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA, 4Division of Laboratory Services, Tennessee Department of Health, Nashville, Tennessee, USA, 5Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA, and 6Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

We describe the first documented case of Jamestown Canyon virus (JCV) in North Carolina, which occurred in a liver transplant patient who presented acutely with headache, aphasia, and confusion. This is also the first report of recovery from JCV encephalitis following treatment with intravenous immune globulin.

Keywords. arboviruses; encephalitis; immunocompromised host; emerging infectious diseases; vector-borne diseases.

A man in his 50s with a history of liver transplantation for alcoholic hepatitis 3 years prior presented at the end of October with 4 days of headache, congestion, and malaise and a few hours of confusion, slurring of words, and stuttering. He had previously treated for rejection 3 months earlier with oral steroids. He lived in Western North Carolina and was an avid woodturner, spinning wood blocks at high speed to shape them into objects. He reported wearing a HEPA filter mask when working with woods known to be toxic. He had recently returned from a woodturners’ conference in a mountainous region of North Carolina and had traveled to New Jersey 1 month before onset of symptoms. He could not recall any recent tick or mosquito bites.

On presentation, his temperature was 38.3°C, heart rate was 85 beats per minute, blood pressure was 167/77, and oxygen saturation was 95% on room air. He was alert and oriented to person, but not place, or time. Initial neurologic exam revealed word finding difficulties and clonus bilaterally, but intact strength, sensation, and cranial nerve function. Laboratory studies were at his baseline (Table 1). Magnetic resonance imaging (MRI) of his brain was normal. He was empirically started on cefepime and admitted to the hospital.

During the first 24 hours of hospitalization, his fever resolved, but he became nonverbal and tremulous with bradykinesia, generalized stiffness, and upper extremity cogwheel rigidity. Intravenous vancomycin, acyclovir, and doxycycline were added to his antimicrobial regimen. Cerebrospinal fluid (CSF) testing on hospital day 2 showed an elevated protein level (78 mg/dL; upper limit of normal 45 mg/dL) and mild lymphocytic pleocytosis with 6 nucleated cells (78% lymphocytes) (Table 1). Blood and CSF cultures and herpes simplex virus CSF polymerase chain reaction (PCR) were negative, so acyclovir and vancomycin were stopped on hospital day 3.

Despite empiric treatment for bacterial meningitis and tick-borne encephalitis, the patient’s mental status did not improve, and fever recurred on hospital day 7. Repeat MRI of the brain was again normal. Given high suspicion for arboviral encephalitis, in particular West Nile virus, he was given 0.5 g/kg (35 g) of intravenous immunoglobulin (IVIG) daily for 4 days (Figure 1). Over the following 3 days, his mental status rapidly improved. Neurologic deficits improved more gradually and did not completely return to baseline. Therefore, on hospital day 16, he received a second course of IVIG (0.5 g/kg/d—35 g daily for 4 days), with further recovery of neurologic function. The patient was discharged home on hospital day 21 with physical and speech therapy for mild residual mobility and speech issues.

An extensive evaluation for infectious and autoimmune causes of his illness was unrevealing (Table 1). A thorough literature review was undertaken to identify potentially relevant exposures from the patient’s woodturning hobby. Although exposure to some solvents used for wood processing has been associated with central nervous system effects [1], we found no case reports of focal neurologic deficits associated with woodworking or turning. Additionally, CSF collected on HD 6 (~10 days after symptom onset) was sent to the University of California–San Francisco (UCSF) for metagenomic sequencing, but no pathogen was detected.

Approximately 2 months after symptom onset, Jamestown Canyon virus and Powassan virus testing performed by the Centers for Disease Control and Prevention (CDC) resulted. Acute phase CSF testing for JCV IgM was positive. Acute CSF JCV plaque reduction neutralization titer (PRNT) was positive at 2 (positive is ≥2), and early convalescent serum JCV PRNT was 320 (positive is considered ≥10) (Figure 1). As the
The initial serum sample was collected after the first IVIG dose, serum obtained 3 months after IVIG treatment was also tested, and the PRNT remained positive at 320, confirming the diagnosis. Human IgG has a half-life of ~30–40 days, and clinical efficacy wanes about 3–4 weeks after therapy [2, 3]; therefore, the 3-month interval should have been more than sufficient to allow for clearance of IVIG. The patient’s deficits completely resolved with rehabilitation therapies ~4 months after illness.

JCV is an orthobunyavirus of the California Encephalitis serogroup that is transmitted by several species of mosquitoes, including Aedes and Culex spp. [4]. Animal and human neutralizing antibody studies suggest that JCV exists throughout North America, with the majority of cases occurring in the Midwest and Northeast United States. Human seroprevalence estimates in the United States are as high as 15%–30% [5, 6]. First detected as a cause of encephalitis in 1997, JCV became a CDC-reportable infection in 2004. Although confirmed human cases are rare, it is an emerging pathogen, with 75, 41, and 25 cases reported in 2017, 2018, and 2019 respectively [7–9]. The discrepancy between serological survey data and reported cases is likely due to underdiagnosis and under-reporting, particularly of less severe cases, at least in part because of the lack of
commercially available diagnostic tests. To our knowledge, this is the only documented case of JCV infection in North Carolina, first reported by the CDC [9, 10]. Two cases have been reported in neighboring Tennessee, but none have been documented in Virginia or South Carolina.

This patient’s immunosuppressive medications may have played a role in increasing his risk for development of neuroinvasive disease from JCV. Calcineurin inhibitors depress the function of both effector and regulatory T cells and affect regulatory B lymphocyte function, all of which are important in responding to acute viral infections [11]. Glucocorticoids have more of an anti-inflammatory effect; they blunt cytokine responses and pro-inflammatory cascades but also impair the migration and function of monocytes, macrophages, and circulating CD4+ T cells [12]. In West Nile virus infection, a related RNA virus that causes neuroinvasive disease in humans, immune suppression does not seem to increase the risk of severe illness, although it has been associated with an increased risk of death [13, 14].

The clinical presentation of JCV infection ranges from asymptomatic to nonspecific febrile illness, meningitis, or encephalitis with a strong male predominance [4, 5]. JCV is associated with high rates of neuroinvasive disease, usually normal CSF parameters, and low fatality rates [5, 15]. However, although rare, JCV has also been found to be associated with chronic infection, viral compartmentalization, and possibly evolution that resulted in a fatal infection [16]. Fever and altered mental status, as seen in this patient, commonly occur. Arboviruses circulate in the blood and CSF transiently early in illness, and often at low levels, which likely explains why JCV was not detected by CSF metagenomic sequencing in the case of our patient [5, 17]. Therefore, diagnosis is primarily made using serology with confirmation by plaque reduction neutralization testing given antibody cross-reactivity among California serogroup arboviruses [4, 18].

As there are no specific antiviral therapies available for JCV, treatment is usually supportive, with most patients making a gradual, full recovery. Although IVIG has been used to treat other viral encephalitides, such as West Nile virus, to our knowledge, this is the first report of its use and association with a clinical response for JCV [19]. There is 1 case report of JCV encephalitis in a solid organ transplant recipient who was treated with ribavirin and had a similarly prolonged course but also ultimately achieved complete recovery [20].

In conclusion, Jamestown Canyon virus is an emerging arboviral infection in the United States that can cause severe neuroinvasive disease in individuals who have undergone solid organ transplantation and are on immunosuppressive medications such as calcineurin inhibitors and glucocorticoids. Therefore, JCV and other arboviral diseases should be considered as potential causes of encephalitis in immunocompromised patients.

Acknowledgments

We would like to thank the patient described in this report for his support of this publication. We would also like to acknowledge Daniel Pastula at the Centers for Disease Control and Prevention for his consultation regarding interpretation of the JCV testing results, David Beckham at the University of Colorado School of Medicine for his advice regarding treatment of arboviral infection with IVIG, and Steve Miller and Charles Chiu at UCSF for conducting the metagenomic sequencing analysis and assisting with its interpretation.

Financial support. This work was supported by the National Heart, Lung, and Blood Institute (T32HL007106 to E.J.C.), the National Institute of Allergy and Infectious Diseases (T32-AI07151 to A.I.M.), and the National Center for Advancing Translational Sciences (TL1TR002491 to M.L.S.), all within the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Potential conflicts of interest. D.V.D. reports grants from NIH, personal fees from Achaogen, personal fees from Shionogi, personal fees from Allergan, personal fees from Astellas, personal fees from Neumedinic, personal fees from T2biosystems, personal fees from Roche, personal fees from Merck, personal fees from Karius, personal fees from Entasis, personal fees from Wellspring, personal fees from Qpex, and personal fees from Pfizer, all outside the submitted work. E.J.C., A.I.M., M.L.S., K.J.L., M.B.M., and C.L.G. do not have any relevant conflicts to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Author contributions. E.J.C. and A.L.M.: conceptualization, writing—original draft, writing—review and editing, visualization. M.L.S.: conceptualization, writing—original draft, writing—review and editing. K.J.L. and M.B.M.: investigation, resources, project administration, writing—review and editing. D.V.D. and C.L.G.: writing—review and editing, supervision.

Patient consent. The patient whose case is described in this article provided verbal and written consent for its publication. This report was also reviewed by the University of North Carolina Institutional Review Board (IRB; 20-3240), and it was determined that it does not constitute human subjects research and therefore did not require IRB approval.

References

1. Health and Safety Executive. Hazardous substances. Available at: https://www.hse.gov.uk/woodworking/hazard.htm. Accessed 9 November 2021.
2. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28:803–19, ix.
3. Rojavina MA, Hubsch A, Lawo J-P: Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency. J Clin Immunol 2016; 36:210–9.
4. Pastula DM, Hoang Johnson DK, Fischer M, White JL, Staples JE, Dupuis AP. Jamestown Canyon virus disease in the United States—2000–2013. Am J Trop Med Hyg 2015; 93:384–9.
5. Piantadosi A, Kanjilal S. Diagnostic approach for arboviral infections in the United States. J Clin Microbiol. 2020; 58:e01926-19. doi:10.1128/JCM.01926-19.
6. Mayo D, Karabatsos N, Scarno FJ, et al. Jamestown Canyon virus: seroprevalence in Connecticut. Emerg Infect Dis 2001; 7:911–2.
7. Kinlessa CM, Paras ML, Smole S, et al. Jamestown Canyon virus in Massachusetts: clinical case series and vector screening. Emerg Microbes Infect 2020; 9:903–12.
8. McDonald E, Martin SW, Landry K, et al. West Nile virus and other domestic nationally notifiable arboviral diseases - United States, 2018. MMWR Mortb Mortal Wkly Rep 2019; 68:673–8.
9. Centers for Disease Control and Prevention. ArboNet. Available at: https://www.cdc.gov/arboretum/maps/A3DB_Diseases_Map/index.html. Accessed 9 November 2021.
10. Curren EJ, Lehman J, Kolsin J, et al. West Nile virus and other nationally notifiable arboviral diseases — United States, 2017. MMWR Mortb Mortal Wkly Rep 2018; 67:1137–42.
11. Tebbe B, Wilde B, Ye Z, et al. Renal transplant recipients treated with calcineurin-inhibitors lack circulating immature transitional CD19+CD24hiCD38hi regulatory B-lymphocytes. PLoS One 2016; 11:e0153170.
12. Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression.” Clin Infect Dis 2021; 73:e1302–17.
13. Lindsey NP, Staples JE, Lehman JA, Fischer M. Medical risk factors for severe West Nile virus disease, United States, 2008-2010. Am J Trop Med Hyg 2012; 87:179–84.
14. Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect 2006; 134:1325–32.
15. Burakoff A, Lehman J, Fischer M, Staples JE, Lindsey NP. West Nile virus and other nationally notifiable arboviral diseases - United States, 2016. MMWR Morb Mortal Wkly Rep 2018; 67:13–7.
16. Solomon IH, Ganesh VS, Yu G, et al. Fatal case of chronic Jamestown Canyon virus encephalitis diagnosed by metagenomic sequencing in patient receiving rituximab. Emerg Infect Dis 2021; 27:238–42.
17. Barzon L, Pacenti M, Ulbert S, Palù G. Latest developments and challenges in the diagnosis of human West Nile virus infection. Expert Rev Anti Infect Ther 2015; 13:327–42.
18. Centers for Disease Control and Prevention. Jamestown Canyon virus: information for healthcare providers. 2021. Available at: https://www.cdc.gov/jamestown-canyon/healthcare-providers/index.html. Accessed 9 November 2021.
19. Gnann JW Jr, Agrawal A, Hart J, et al. Lack of efficacy of high-titered immunoglobulin in patients with West Nile virus central nervous system disease. Emerg Infect Dis 2019; 25:2064–73.
20. Askar W, Menaria P, Thohan V, Brummitt CF. Jamestown Canyon virus encephalitis in a heart transplant patient. Transpl Infect Dis 2020; 22:e13210.